Exemplos de uso de Was not carcinogenic em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Etoricoxib was not carcinogenic in mice.
Two-year studies in mice andrats to assess the carcinogenic potential of ivacaftor demonstrated that ivacaftor was not carcinogenic in either species.
Atorvastatin was not carcinogenic in rats.
In their evaluation of toxicity for the Joint FAO/WHO Meeting on Pesticide Residues(JMPR, 2003),WHO concluded that“the weight of evidence suggested that paraquat was not carcinogenic in the rat.
Sitagliptin was not carcinogenic in mice.
Daclatasvir was not carcinogenic in mice or in rats at exposures 8-fold or 4-fold, respectively, the clinical AUC exposure.
BfR, EFSA and ECHA played off one type of statistical test against another,arguing that glyphosate was not carcinogenic because significance in cancer incidence was only achieved in one type of test and not in another.
Teysuno was not carcinogenic in either the rat or the mouse.
Abiraterone acetate was not carcinogenic in female rats.
Laropiprant was not carcinogenic in 2 year studies in mice and rats at the highest doses tested, which represents at least 218 to 289 times the human exposure based on the AUC of the recommended daily human dose.
Sitagliptin was not carcinogenic in mice.
Evolocumab was not carcinogenic in hamsters at exposures much higher than patients receiving evolocumab at 420 mg once monthly.
Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures similar to those at the maximum recommended human dose, based on AUC.
Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice.
Umeclidinium was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in mice or rats at exposures 26 or 22-fold, times the human clinical exposure of umeclidinium 55 micrograms, based on AUC, respectively.
Ombitasvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested(150 mg/kg/day), resulting in ombitasvir AUC exposures approximately 26-fold higher than those in humans at the recommended clinical dose of 25 mg.
Etravirine was not carcinogenic in rats and in male mice.
Rasagiline was not carcinogenic in rats at systemic exposure, 84- 339 times the expected plasma exposures in humans at 1 mg/day.
Ruxolitinib was not carcinogenic in the Tg. rasH2 transgenic mouse model.
Dolutegravir was not carcinogenic in long term studies in the mouse and rat.
Ledipasvir was not carcinogenic in the 6-month rasH2 transgenic mouse study at exposures up to 26-fold higher than human exposure.
Cabozantinib was not carcinogenic in the rasH2 mouse model at a slightly higher exposure than the intended human therapeutic exposure.
Deferasirox was not carcinogenic when administered to rats in a 2-year study and transgenic p53+/- heterozygous mice in a 6-month study.
Similarly, dasabuvir was not carcinogenic in a 2-year rat study up to the highest dose tested(800 mg/kg/day), resulting in dasabuvir exposures approximately 19-fold higher than those in humans at 500 mg.
Similarly, ombitasvir was not carcinogenic in a 2-year rat study up to the highest dose tested(30 mg per kg per day), resulting in ombitasvir exposures approximately 16-fold higher than those in humans at 25 mg.
Similarly, paritaprevir/ritonavir was not carcinogenic in a 2-year rat study up to the highest dosage tested(300 mg/30 mg/kg/day), resulting in paritaprevir AUC exposures approximately 8-fold higher than those in humans at 150 mg.
Dasabuvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested(2 g/kg/day), resulting in dasabuvir AUC exposures approximately 19-fold higher than those in humans at the recommended dose of 500 mg 250 mg twice daily.
Paritaprevir/ritonavir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested(300 mg/30 mg/kg/day), resulting in paritaprevir AUC exposures approximately 38-fold higher than those in humans at the recommended dose of 150 mg.
Studies show that the product is not carcinogenic, and allergic reactions are extremely rare.
Ketoconazole is not carcinogenic.